Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer by Vos, M.C. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/165697
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
RESEARCH Open Access
Limited independent prognostic value of
MMP-14 and MMP-2 expression in ovarian
cancer
M. Caroline Vos1*, Anneke A. M. van der Wurff2, Johan Bulten3, Roy Kruitwagen4,5, Harrie Feijen6,
Toin H. van Kuppevelt7, Thijs Hendriks8 and Leon F. A. G. Massuger9
Abstract
Background: In cancer, various MMPs play a role in progression and metastasis and their overexpression generally
indicates a poor prognosis. MMP-14 is the main activator of MMP-2 and both molecules play a role in normal
ovarian follicular development. Earlier reports indicated a prognostic value for both MMP-14 and MMP-2 in ovarian
cancer. This study was designed to determine the prognostic value of MMP-14 and MMP-2 expression in ovarian
cancer with data on long-term follow-up.
Methods: Tumor samples of 94 consecutive ovarian cancer patients from one regional laboratory were evaluated.
Clinical and survival data were collected and related to known prognostic factors, as well as to
the expression of MMP-14 and MMP-2 as determined by semi-quantitative immunohistochemistry.
Results: Epithelial MMP-14 expression correlated with stromal MMP-14 expression (rho = .47, p < .01) and epithelial
MMP-2 expression was found to correlate with both MMP-14 epithelial and stromal expression (rho = −.28, p < .01
respectively rho = −.21, p < .05). In univariable analysis of 64 advanced-staged tumours, no MMP parameter was
significant for progression-free or overall survival. In multivariable analysis for PFS, stromal MMP-14 expression and
epithelial MMP-2 expression remained in the model. For overall survival, no MMP parameter showed significance.
Conclusions: We confirmed the correlation between epithelial and stromal MMP-14 expression and between
epithelial MMP-2 and both epithelial and stromal MMP-14 expression. In this study with long-term follow-up, the
independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer is limited to a role in PFS for
stromal MMP-14 expression and epithelial MMP-2 expression.
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Background
An important distinguishing feature of ovarian cancer is
the low survival rate of patients [1]. Screening is not
possible, and because symptoms occur late in the disease
process, most patients are diagnosed with advanced-
stage disease. Although the majority of these patients
respond well to first-line treatment, eventually only 43.5 %
of them survive more than 5 years [1]. Several well-
researched factors influence survival, including age, stage,
histological subtype and residual tumor after debulking
surgery [2].
In search for prognostic markers that could be useful
in managing ovarian cancer, we focused on MMP-14
and MMP-2. Matrix metalloproteinases (MMPs) are zinc-
dependent proteases that are involved in degrading the
extracellular matrix in normal physiological processes,
such as reproduction, embryonic development and tissue
remodeling, as well as in disease processes, including
arthritis and cancer [3]. In normal ovarian physiology,
MMP-14, the first described membranebound MMP, is
involved in follicular growth. Concurrently, it is also the
main activator of MMP-2 or gelatinase A, which is found in
large quantities in follicular fluid and the corpus luteum [4].
* Correspondence: c.vos@elisabeth.nl
1Department of Obstetrics and Gynaecology, Elisabeth Tweesteden Hospital,
PO Box 90151, 5000 LC Tilburg, The Netherlands
Full list of author information is available at the end of the article
© 2016 Vos et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Vos et al. Diagnostic Pathology  (2016) 11:34 
DOI 10.1186/s13000-016-0485-3
In cancer, MMP-14 is also the main activator of MMP-2,
which is then secreted into the extracellular matrix [5]. In
many types of cancer, various MMPs play a role in
progression and metastasis [3]. In general, they are overex-
pressed in primary and metastatic tumors with a poor
prognosis. Therefore, MMP inhibition seems to be an
attractive approach in treating cancer. Classical MMP
inhibitors, including Marimastat, have been studied
with mixed results, and antibodies against MMP-14 are
currently being investigated [6–8].
In ovarian cancer, overexpression of MMPs such as
MMP-2, MMP-7, MMP-9, MMP-11 and MMP-14 has
been reported and correlated with invasion and metasta-
sis [6]. Using immunohistochemistry, high expression of
MMP-14 has been demonstrated in ovarian clear-cell
carcinomas. This histotype is known for it’s poor progno-
sis [9]. MMP-14 and MMP-2 also appear to be overex-
pressed in serous and mucinous malignant ovarian tumor
epithelium, while benign and borderline tumors show
lower levels of expression [10]. Overexpression of MMP-
14 and MMP-2 is significantly associated with a shorter
disease-specific survival in ovarian cancer [11], although
Brun et al. found that this association lost its signifi-
cance after Bonferroni correction [12]. Also, Trudel et
al. found little independent prognostic value for MMP-
14 expression [13]. Most of these studies were per-
formed at large referral centres, which may have influ-
enced the results due to selection bias, where the
younger and fitter patients are referred more easily
than the elderly and frail patients.
The aim of the present study is to evaluate the prognos-
tic value of MMP-14 and MMP-2 expression in ovarian
cancer, as determined by semi-quantitative immunohisto-
chemistry, in a large regional cohort. In our cohort, long-
term survival 10–15 years after initial diagnosis could be
determined.
Methods
Patients
This retrospective cohort study included all 116 patients
diagnosed with ovarian cancer at St. Elisabeth Hospital and
Tweesteden Hospital, both in Tilburg, the Netherlands,
and at Amphia Hospital, in Breda, the Netherlands,
between January 1997 and December 2003. They were
followed until March 1, 2013. Patients who had under-
gone neoadjuvant chemotherapy with secondary cytore-
ductive surgery were excluded (n = 11), because previous
chemotherapy may have influenced MMP expression in
the immunohistochemical results at the time of surgery
[14]. Four patients were lost to follow-up because they
emigrated. In seven patients, no residual tumor material
was available, leaving 94 patients for analysis of MMP-14
and MMP-2 expression.
Prognostic factors
Clinical prognostic factors were collected from the pa-
tients’ medical records. FIGO stage (I to IV), histology,
and differentiation grade were categorized according to
the World Health Organization (WHO) criteria, grade
being assigned according to the observer’s impression of
architectural and cytological features [15, 16]. All histo-
pathological results and previous slides were reviewed by
two pathologists (AAW, JB). If they disagreed, consensus
was found between them. Serum levels of CA-125 were
determined preoperatively. Ascites volume was deter-
mined at the time of collection or surgery. Debulking
surgery was found to be optimal if the maximum diame-
ters (length, width, or depth) of the individual residual
tumour deposits were all less than 1 cm.
Treatment
In accordance with uniform treatment guidelines, all pa-
tients underwent a staging laparotomy in the event of
clinical early-stage ovarian cancer, or a debulking proced-
ure in the event of advanced-stage ovarian cancer. In
patients with FIGO stage Ia or Ib ovarian cancer with
differentiation grade I, no adjuvant therapy was given.
All other patients received 6 to 9 courses of adjuvant
platinum-based chemotherapy.
Outcome
The interval between diagnosis and detection of disease
progression (progression-free survival, PFS) and between
diagnosis and death (overall survival, OS) were considered
as end points. PFS was defined as the time (months) until
progression after partial response/stable disease, or the
time until recurrence after complete response. Disease
progression was established if clinical symptoms (re-)
appeared and/or ultrasound or computed tomography
showed that recurrent tumor lesions had appeared or
increased, often accompanied by a rise in CA 125. Pa-
tients who showed progression during first-line treatment
were coded as having a PFS of 0 months. Information on
the date of death and cause of death was derived from
medical charts, hospital-registered death certificates, and
death registrations by the patient’s general practitioner.
Patients who had neither progressed nor died before
March 1, 2013 were censored at the last follow-up date. If
patients had died, but not from ovarian cancer, they were
censored at the time of death.
Semiquantitative immunohistochemistry
From the archives of the histopathology laboratory,
paraffin-embedded blocks were selected. Semiquantative
immunohistochemistry was performed as described before
[17]. In short, after deparaffinisation in xylene and hydra-
tion in graded alcohol, sections of 3 μm were used. Each
slide included positive controls (placenta). For blocking of
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endogenous peroxidase, 3 % H2O2 and 5 % normal goat
serum was used. Slides were washed three times with
phosphate-buffered saline (PBS) after each incubation
step. As the primary antibody for MMP-2, a monoclonal
antibody was used (clone A-Gel vc2, Thermo Scientific)
[18] Incubation was in a dilution 1: 10 overnight at 4 °C.
As the primary antibody for MMP-14, a polyclonal anti-
body (Thermo Scientific) [5] was used in a dilution 1:20
for 60 min at room temperature. As the secondary anti-
body, poly-HRP-GAM/R/R IgG Powervision (Immuno-
logic, Duiven, the Netherlands) was used for 60 min at
room temperature. Each run contained negative controls
(i.e. without primary antibody). Staining was done
twice with diaminobenzidine (Immunologic, Duiven,
the Netherlands) in substrate buffer (20 μl) for 5 min.
Counterstaining was performed with hematoxylin.
The scoring system that was used incorporated both
the intensity of the scoring (0 = absent, 1 = weak, 2 =mod-
erate, 3 = strong) and the percentage of positive tumor
cells (0 = 0 %, 1 = 1–25 %, 2 = 26–50 %, 3 = 51–75 %, 4 =
76–100 %). Stromal staining was recorded separately as
no, weak or strong staining. Points for the intensity and
the percentage of staining were added and assigned an
Overall Score according to Kamat [11]. The Overall Score
was dichotomized in 0 for no-to-weak expression (1–2
points) and 1 for moderate to-strong expression (3–6
points). Two investigators (MCV, AAW) scored all slides
for MMP staining. If they disagreed, consensus was
reached between them.
Statistical analysis
Statistical analysis was performed using the Statistical Pack-
age for Social Sciences 20.0 (SPSS Inc., Chicago, Il). Patient
characteristics and correlations, as well as median PFS and
OS, were computed and using the Kaplan-Meier method,
survival curves were plotted. As early-stage patients have a
relatively favourable prognosis, Cox regression survival ana-
lyses were performed for traditional clinicopathological and
MMP variables only in the advanced-stage group of 64
patients. To correct for the relatively small sample size the
Cox regression analysis was bootstrapped 1000 times in
order to detect potential significance for MMP variables. A
model was built using a backward selection procedure in
Cox regression analysis, where all variables were manually
deleted step by step for p values greater than 0.10. In this
model, the traditional clinical prognostic factors – i.e. age,
FIGO stage, histology, differentiation and cytoreduction –
were included together with MMP-14 and MMP-2 Overall
Scores and stromal staining. The use of more variables than
these would violate the number-of-events-per-variable rule.
Results
The patient characteristics are summarized in Table 1. Me-
dian follow-up time was 59 months (range 0–195 months).
The cohort consisted of all consecutive patients from a
regional laboratory, including 30 early-stage patients. All
the patients were treated according to the guidelines that
were in effect at the time of treatment (1997-2003).
MMP-14 and MMP-2 expression was found in most
of the tumours investigated, not only in the epithelium,
but in a proportion of tumours also in the stroma.
Results of MMP-staining are shown in Table 2. Staining
was mainly pericellular for MMP-2 and mainly both
cytoplasmatic and pericellular for MMP-14 if staining
was epithelial (Fig. 1). Stromal staining was mainly
diffuse. This is illustrated in Fig. 1, which shows repre-
sentative slides of both MMP-14 and MMP-2 staining.
Clearly, the stroma of a serous carcinoma stains positive
for MMP-14 (1a) and negative for MMP-2 (1b). A case
of clear-cell carcinoma shows intense expression for
MMP-14 (1c) and less intense expression for MMP-2
(1d).
Table 1 Patient characteristics
Early stage (n = 30) Advanced stage (n = 64)
Median (range) Frequency Median (range) Frequency
Age 50 (25–73) 59 (31–88)
Histology
Serous 5 32
Mucinous 13 2
Endometroid 4 14
Clear cell 3 4
Adenocarcinoma
unspecified
3 12
Mixed 2 0
Differentiation
Low-grade 16 8
High-grade 14 56
CA 125 24 (0–4325) 321 (0–44438)
Ascites
Absent 23 15
Present 7 49
FIGO stage
IIB 11
III 44
IV 9
Cytoreduction (only
advanced stage disease)
Optimal 35
Suboptimal 29
Progression Free
Survival
116 (0–195) 17 (0–191)
Overall Survival 120 (0–195) 34 (0–191)
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Seven patients in the whole cohort had a clear-cell
carcinoma, which is known for it’s high level of MMP-14
expression: of these patients only one patient showed no
epithelial and stromal MMP-14 staining and no MMP-2
stromal staining; epithelial MMP-2 staining however, was
present in this patient. Six other patients with a clear-cell
carcinoma showed epithelial MMP-14 staining of which
two had no stromal MMP-14 staining. For MMP-2, the
same pattern was observed in these two patients i.e. epi-
thelial MMP-2 staining without stromal MMP-2 staining.
Only one patient with a clear-cell carcinoma had both
epithelial and stromal MMP-14 and MMP-2 expression.
Nor epithelial MMP-14 and MMP-2 expression, nor stro-
mal MMP-14 and MMP-2 expression was related to stage
or survival in these seven patients with a clear-cell carcin-
oma. In all other histotypes, patients with both high and
low expression of MMP-14 and/or MMP-2 in the epithe-
lial and stromal compartment were found.
MMP-14 Overall Score correlated with MMP-14 in
stroma and with MMP-2 Overall Score. The correlation
coefficient of .47 between MMP-14 Overall Score in the
tumour epithelium and MMP-14 in stroma indicates a
strong relation. Also, MMP-14 in stroma and MMP-2
Overall Score correlated. The Spearman correlation co-
efficients between MMP-14 Overall Score and MMP-2
Overall Score and between MMP-2 Overall Score and
MMP-14 in stroma, which were .28 respectively .21, indi-
cate a moderate effect (Table 3).
Considering the FIGO stage of patients, positive Over-
all Score for MMP-14 and MMP-2 differed between the
two proteins. MMP-2 expression frequency is high in
both early- and advanced-stage patients (28/30 respect-
ively 55/64), while MMP-14 expression is less often
present in both groups (20/30 respectively 33/64). See
Fig. 2.
As Table 4 shows, univariable Cox regression analysis
for PFS in 64 advanced-stage patients demonstrated a
trend for MMP-14 stromal expression (HR 1.421 (95 %
Confidence Interval 0.99–2.039, p 0.057). For overall
Table 2 MMP-14 expression and MMP-2 expression (numbers
of patients)
Early stage
(n = 30)
Advanced stage
(n = 64)
MMP-14 Overall Score (number of patients)
0 10 31
1 20 33
MMP-14 stroma (number of patients)
No 12 26
Weak 3 4
Strong 15 34
MMP-2 Overall Score (number of patients)
0 2 9
1 28 55
MMP-2 stroma (number of patients)
No 18 47
Weak 2 4
Strong 10 13
MMP Matrix Metalloproteinase
Fig. 1 MMP-14 and MMP-2 staining. a MMP-14 staining of serous adenocarcinoma. b MMP-2 staining of serous adenocarcinoma. c MMP-14
staining of clear-cell carcinoma. d MMP-2 staining of clear-cell carcinoma
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survival, only age, histology and FIGO stage were signifi-
cant after such analysis. None of the other MMP-14 or
MMP-2 related parameters showed correlation with either
PFS or OS in univariable analysis. Since bootstrapping our
univariable Cox regression analysis did not result in new
significant factors, it was decided to present the results
without bootstrapping. In a multivariable Cox regression
model in advanced-stage patients, aimed at identifying
prognostic factors, age (p < .05), differentiation (p < .07),
FIGO stage (p < .02), cytoreduction (p < .10), MMP-14
in stroma (p < .01) and MMP-2 Overall Score (p < .03)
remained in the model for PFS. After bootstrapping,
only FIGO stage (p < .04) and MMP-14 in stroma (p < .06)
remained in the model for PFS. In multivariable analysis
for OS, age (p < .00), histology (p < .00) and FIGO stage
(p < .00) remained significant. After bootstrapping, only
age (p < .03) and FIGO stage (p < .03) remained in the
model for OS. In our group of nine FIGO IV patients,
three patients were long-term survivors in spite of their
FIGO IV stage disease. This may explain the lack of
significance for this group in multivariable analysis.
Figure 3 shows Kaplan-Meier curves for MMP-14 Over-
all Score for PFS and OS in advanced-stage patients,
illustrating the lack of significance of MMP-14 expression
in PFS or OS.
Discussion
The findings in this study are in contrast with the
previously reported promising prognostic values for
MMP-14 and MMP-2 in ovarian cancer [11, 19], but
underline the later reports by Brun et al. [12] and
Trudel et al. [13] This large retrospective cohort study
with long-term follow-up has shown a correlation be-
tween epithelial MMP-14 and MMP-2 expression, and for
both with stromal MMP-14 expression. No MMP param-
eter has been found to be a significant prognosticator for
progression-free survival or overall survival in univariable
analysis, while known clinical and histopathological prog-
nostic parameters (age, histology and FIGO stage) were
for overall survival. In multivariable analysis for PFS,
MMP-14 stromal staining and MMP-2 epithelial staining
remained in the model. For overall survival, no MMP par-
ameter was found to be a prognosticator.
The strengths of the present study are the use of a
regional cohort with long-term follow-up and the use of
immunohistochemistry in a diagnostic laboratory facility.
Due to the use of a regional cohort, it is unlikely that
the results of present study are strongly influenced by
patient selection. The long-term follow-up eliminates bias
by short-term outcomes. By using immunohistochemistry
in a diagnostic laboratory facility, bias due the lack of
reproducibility of our results is unlikely.
A possible limitation of the present study is the exclu-
sion of the patients who were treated with neo-adjuvant
chemotherapy, but this is only a small group in this
cohort.
The magnitude of the correlations between the presence
of MMP-14 in the tumour epithelium and MMP-14 in the
Table 3 Spearman correlations between MMP-14 and MMP-2
expression
MMP-14 OS MMP-14 stroma MMP-2 OS
MMP-14 Overall Score
MMP-14 stroma .47**
MMP-2 Overall Score .28** .21*
MMP-2 stroma 0.03 0.1 0.04
MMP Matrix MetalloProteinase
**. Correlation is significant at the 0.01 level (2-tailed)
*. Correlation is significant at the 0.05 level (2-tailed)
Fig. 2 MMP-14 and MMP-2 Overall Score by FIGO stage. On the Y-axis the number of patients is given. OS = Overall Score
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tumour stroma indicate a strong effect. At the base of the
invadopodia of the tumour cell, the activation of MMP-2
by MMP-14 takes place, so the observed correlation
between MMP-14 and MMP-2 that has been found in
other studies, is confirmed in our study [3, 5].
The comparison between the results of this and other
studies on prognosis can be focussed on three factors:
technical or procedural differences, tumor biology and/
or selection of patients with different tumor biology for
the studies.
With respect to techniques and procedures used in
the different studies, the following observations can
be made.
Similarly to the present study, all other studies that
are cited here made use of immunohistochemistry. In
addition, comparable primary antibodies were used, i.e.
polyclonal antibodies for MMP-14 and a monoclonal
antibody for MMP-2 [9–13]. Immunohistochemical re-
sults may also be influenced by differences in storage
conditions of the tissue blocks [20]. All the cited stud-
ies used material collected over a lengthy time period
(5–20 years). These technical aspects are comparable
between the different studies and probably not the
explanation for the differences between the results.
However, differences in fixation protocols between the
laboratories may explain the differences in results.
The second possible explanation for differences in
results is tumor biology. The first factor to consider in
this context is histologic subtype. As we did, Adley et al.
found high MMP-14 expression in clear-cell carcinomas
[6]. Expression of MMP-14 in serous and mucinous
malignant epithelial cells has also been found [10]. In
our cohort, MMP-14 and MMP-2 expression are not
confined to clear-cell carcinomas, and not all clear-cell
carcinomas express both proteins. Therefore, the differ-
ences in prognostic value of MMP-14 are not only attrib-
utable to histological subtype or selection by histological
subtype.
Tumor stage is the following important factor in
tumour biology and also an important prognosticator. In
our cohort, high MMP-14 expression was found in two
thirds of early-stage tumours whereas in the advanced-
Table 4 Hazard ratio's, 95 % confidence intervals and significance for progression-free survival and overall survival of advanced stage
patients (significant factors are shown in bold)
Progression free survival Overall survival
HR 95,0 % CI for HR Sig. HR 95,0 % CI for HR Sig.
Lower Upper Lower Upper
Age 1.019 0.986 1.053 0.266 1.028 1.003 1.054 0.03
Histology 0.641 0.003
Mucinous versus serous 1.134 0.498 2.583 0.765 1.223 0.605 2.471 0.575
Endometroid versus serous 0 0 . 0.983 21.448 3.539 130.006 0.001
Clear-cell versus serous 0.542 0.187 1.575 0.261 0.559 0.228 1.369 0.203
Adenocarcinoma unspecified versus serous 1.099 0.231 5.226 0.906 1.335 0.369 4.835 0.66
Differentiation 3.266 0.778 13.716 0.106 1.702 0.674 4.297 0.26
CA 125
<35 0.362 0.635
35–200 0.57 0.216 1.499 0.254 0.847 0.391 1.831 0.672
>200 0.62 0.254 1.515 0.295 0.709 0.34 1.478 0.359
Ascites 1.919 0.836 4.401 0.124 1.75 0.877 3.489 0.112
FIGO
IIB 0.076 0.044
III 0.311 0.077 1.26 0.102 0.294 0.101 0.854 0.024
IV 1.06 0.371 3.028 0.914 0.839 0.389 1.807 0.653
Cytoreduction 1.882 0.939 3.774 0.075 1.696 0.935 3.076 0.082
MMP-14 Overall Score 1.538 0.777 3.043 0.216 0.945 0.551 1.624 0.839
MMP-14 stroma 1.421 0.99 2.039 0.057 0.695 0.371 1.299 0.254
MMP-2 Overall Score 22.901 0 #######* 0.668 0.879 0.395 1.953 0.751
MMP-2 stroma 1.214 0.807 1.828 0.352 1.15 0.832 1.59 0.399
HR Hazard Ratio, CI Confidence Interval, Sig. Significance, MMP Matrix Metalloproteinase
* = because of the low number of patients 95 % CI can not be calculated
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stage group only in half of the tumours high expression
was found. For MMP-2, we found high expression not
only in early-stage but also in advanced-stage tumors. A
third possible explanation for the difference in results is
patient selection, where patients with different prognosis
may be overrepresented in some studies.
Kamat et al. investigated a series of 90 patients by
means of immunohistochemistry and found a correlation
between both epithelial and stromal MMP-14 expression
and prognosis. As 90 % of their patients had advanced-
stage disease, the expression pattern that they found
may mainly reflect advanced-stage pathophysiology [11].
Also, they found stromal expression in 87 of their 90
patients, whereas we found such expression in only 52
of our 94 patients. Therefore, the difference between the
Kamat series and our data may be due to selection of the
patients, their series was collected at a large referral centre.
In line with our results, Brun et al. also found no inde-
pendent prognostic value for MMP-14 and MMP-2 ex-
pression [12]. Their series comprised only advanced-stage
tumours, with higher median age, CA 125 and percentage
of interval debulking than in the present study. Trudel et
al. investigated 211 tumor arrays after debulking surgery,
where higher MMP-14 expression was associated with fac-
tors of better ovarian carcinoma prognosis. However, after
correction for the known prognostic factors no prognostic
value was found [13]. These results are more in accord-
ance with our results than are the results from Davidson
et al. [19] and Kamat et al. [11].
Conclusion
Having investigated a regional cohort of 94 ovarian cancer
patients by means of semiquantitative immunohistochem-
istry for MMP-14 and MMP-2, we found that epithelial
MMP-14 and epithelial MMP-2 expression correlate. Fur-
thermore, both correlate also with stromal MMP-14. In
our cohort, no MMP parameter was significant in univari-
able analysis for progression-free survival in advanced-
stage patients. In multivariable analysis for PFS, MMP-14
stromal expression and MMP-2 epithelial expression re-
mained in the model with five other factors. For overall
survival, no MMP parameter was significant in uni- or
multivariable analysis. Thus the independent prognostic
value of MMP-2 and MMP-14 expression in ovarian
cancer is limited.
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Fig. 3 Kaplan-Meier curves of PFS and OS for advanced-stage patients by MMP-14 Overall Score
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